Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHYOX2: Nedosiran in Primary Hyperoxaluria
NCT03847909Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2) comparing Nedosiran with Placebo (2 arms). Primary endpoint: Area Under the Curve of Percent Change from Baseline in 24-Hour Urinary Oxalate. Started Oct 2019; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)
Beyond the preview
Go deeper on NCT03847909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847909.